Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
REDWOOD CITY, Calif., Feb. 25, 2016 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report fourth quarter and full year 2015 financial results after market close on Thursday, March 3, 2016. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 855 890 8665 |
| International | 720 634 2938 | |
| Passcode | 50851945 | |
| Live Webcast: | Codexis IR Website | |
| The webcast will be archived for 30 days. | ||
| Replay: | U.S. | 855 859 2056 |
| International | 404 537 3406 | |
| Passcode | 50851945 | |
| The replay will be available for 48 hours | ||
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
| CONTACT: | Investors |
| LHA | |
| Jody Cain, 310 691 7100 | |
| [email protected] | |
| Media | |
| That’s Nice | |
| Guy Tiene, 212 366 4455 | |
| [email protected] |
